Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Biography

Previous academic placements: LLR Clinical Training Fellowship/PhD (2007-2011) Imperial College London. NIHR Academic Clinical Lectureship in Paediatric Haematology (2011-2015) Imperial College London. Bloodwise Clinician Scientist (2015-2020) at University of Oxford.

Clinical training: MBBS and postgraduate Paediatric training, Christian Medical College Vellore, India. Paediatric training (SHO and SpR), London, UK. Integrated Academic Clinical Training programme in Paediatric Haematology, London, UK

Anindita Roy

MRCPCH FRCPath PhD


Associate Professor of Paediatric Haematology

  • Wellcome Trust Clinical Research Career Development Fellow
  • Honorary Clinical Lecturer in Paediatric Haematology, Great Ormond Street Hospital, London

Main research interest: understanding the origins and biology of childhood leukaemia.

Research focus

The main focus of my research is to study prenatal B lymphopoiesis in order to understand the origins of childhood leukaemia, in particular infant acute lymphoblastic leukaemia (ALL). Prenatal B lymphopoiesis is different from adult B cell development; and developmentally-regulated characteristics of fetal B-progenitors are likely to provide the 'oncogenic' cellular context necessary to co-operate with MLL rearrangements to induce infant ALL.  We have recently defined the B lymphoid developmental hierarchy before birth, and my research aims to identify the target cell population for leukaemia initiation in infant ALL. Characterisation of the target cell by molecular and functional assays, including differences in leukaemia models generated, when compared to postnatal cells, will allow us to identify specific pathways that can be targeted for future therapies. I work closely with Prof Irene Roberts investigating how trisomy 21 perturbs haematopoiesis before birth and its implications for Down syndrome associated leukaemias in children.

My vision going forward is to lead a research programme focusing on childhood leukaemias where the need is greatest; of note, including strategies for treatment reduction as well as identification of new or repurposed drugs. As a Paediatric Haematologist, I hope to play a crucial role in implementing research findings into clinical practice, including in LMIC. I am also passionate about mentoring the next generation of clinician scientists.